Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome

Min Goo Lee, Myung Ho Jeong, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung-Woon Rha, Chong Jin Kim, Donghoon Choi, Yang Soo JangJunghan Yoon, Wook Sung Chung, Ki Bae Seung, Seung Jung Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS). Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005 - December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (allcause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448). Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR.

Original languageEnglish
Pages (from-to)2120-2127
Number of pages8
JournalCirculation Journal
Volume75
Issue number9
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Sirolimus
Paclitaxel
Stents
Myocardial Infarction
Percutaneous Coronary Intervention
ST Elevation Myocardial Infarction
zotarolimus
Thrombosis
Incidence

Keywords

  • Drug-eluting stent
  • Metabolic syndrome
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. / Lee, Min Goo; Jeong, Myung Ho; Ahn, Youngkeun; Cho, Jeong Gwan; Park, Jong Chun; Kang, Jung Chaee; Chae, Shung Chull; Hur, Seung Ho; Hong, Taek Jong; Kim, Young Jo; Seong, In Whan; Chae, Jei Keon; Rhew, Jay Young; Chae, In Ho; Cho, Myeong Chan; Bae, Jang Ho; Rha, Seung-Woon; Kim, Chong Jin; Choi, Donghoon; Jang, Yang Soo; Yoon, Junghan; Chung, Wook Sung; Seung, Ki Bae; Park, Seung Jung.

In: Circulation Journal, Vol. 75, No. 9, 01.09.2011, p. 2120-2127.

Research output: Contribution to journalArticle

Lee, MG, Jeong, MH, Ahn, Y, Cho, JG, Park, JC, Kang, JC, Chae, SC, Hur, SH, Hong, TJ, Kim, YJ, Seong, IW, Chae, JK, Rhew, JY, Chae, IH, Cho, MC, Bae, JH, Rha, S-W, Kim, CJ, Choi, D, Jang, YS, Yoon, J, Chung, WS, Seung, KB & Park, SJ 2011, 'Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome', Circulation Journal, vol. 75, no. 9, pp. 2120-2127. https://doi.org/10.1253/circj.CJ-11-0263
Lee, Min Goo ; Jeong, Myung Ho ; Ahn, Youngkeun ; Cho, Jeong Gwan ; Park, Jong Chun ; Kang, Jung Chaee ; Chae, Shung Chull ; Hur, Seung Ho ; Hong, Taek Jong ; Kim, Young Jo ; Seong, In Whan ; Chae, Jei Keon ; Rhew, Jay Young ; Chae, In Ho ; Cho, Myeong Chan ; Bae, Jang Ho ; Rha, Seung-Woon ; Kim, Chong Jin ; Choi, Donghoon ; Jang, Yang Soo ; Yoon, Junghan ; Chung, Wook Sung ; Seung, Ki Bae ; Park, Seung Jung. / Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome. In: Circulation Journal. 2011 ; Vol. 75, No. 9. pp. 2120-2127.
@article{34bbf84e53754061afd2443ad970f30f,
title = "Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome",
abstract = "Background: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS). Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005 - December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (allcause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9{\%}, 9.1{\%}, and 11.0{\%}, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3{\%} in PES group, 0.4{\%} in SES group, and 0.4{\%} in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9{\%} in PES group, 1.0{\%} in SES group, and 1.3{\%} in ZES group, respectively, P=0.448). Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR.",
keywords = "Drug-eluting stent, Metabolic syndrome, Myocardial infarction",
author = "Lee, {Min Goo} and Jeong, {Myung Ho} and Youngkeun Ahn and Cho, {Jeong Gwan} and Park, {Jong Chun} and Kang, {Jung Chaee} and Chae, {Shung Chull} and Hur, {Seung Ho} and Hong, {Taek Jong} and Kim, {Young Jo} and Seong, {In Whan} and Chae, {Jei Keon} and Rhew, {Jay Young} and Chae, {In Ho} and Cho, {Myeong Chan} and Bae, {Jang Ho} and Seung-Woon Rha and Kim, {Chong Jin} and Donghoon Choi and Jang, {Yang Soo} and Junghan Yoon and Chung, {Wook Sung} and Seung, {Ki Bae} and Park, {Seung Jung}",
year = "2011",
month = "9",
day = "1",
doi = "10.1253/circj.CJ-11-0263",
language = "English",
volume = "75",
pages = "2120--2127",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "9",

}

TY - JOUR

T1 - Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome

AU - Lee, Min Goo

AU - Jeong, Myung Ho

AU - Ahn, Youngkeun

AU - Cho, Jeong Gwan

AU - Park, Jong Chun

AU - Kang, Jung Chaee

AU - Chae, Shung Chull

AU - Hur, Seung Ho

AU - Hong, Taek Jong

AU - Kim, Young Jo

AU - Seong, In Whan

AU - Chae, Jei Keon

AU - Rhew, Jay Young

AU - Chae, In Ho

AU - Cho, Myeong Chan

AU - Bae, Jang Ho

AU - Rha, Seung-Woon

AU - Kim, Chong Jin

AU - Choi, Donghoon

AU - Jang, Yang Soo

AU - Yoon, Junghan

AU - Chung, Wook Sung

AU - Seung, Ki Bae

AU - Park, Seung Jung

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS). Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005 - December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (allcause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448). Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR.

AB - Background: The purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (PES), sirolimus-eluting stent (SES), and zotarolimus-eluting stent (ZES) in primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI) with metabolic syndrome (MS). Methods and Results: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005 - December 2007), a total of 1,768 MS patients with STEMI who underwent primary PCI were enrolled: The PES group was 634, SES group, 906, and ZES group, 228. The primary endpoint was major adverse cardiac event (allcause death, re-myocardial infarction, target lesion revascularization) during 12 months follow-up. At 12 months, the cumulative incidence of primary endpoint in the PES, SES, and ZES groups was 10.9%, 9.1%, and 11.0%, respectively (P=0.086). Incidence of death, recurrent myocardial infarction, or target lesion revascularization did not differ among the 3 groups. There were 7 episodes of acute (0.3% in PES group, 0.4% in SES group, and 0.4% in ZES group, respectively, P=0.773) and 18 episodes of cumulative stent thrombosis including late stent thrombosis (0.9% in PES group, 1.0% in SES group, and 1.3% in ZES group, respectively, P=0.448). Conclusions: Implantation of SES, PES, and ZES in MS patients with STEMI undergoing primary PCI provided comparable clinical outcomes in patients enrolled in KAMIR.

KW - Drug-eluting stent

KW - Metabolic syndrome

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=80052157400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052157400&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-11-0263

DO - 10.1253/circj.CJ-11-0263

M3 - Article

C2 - 21757819

AN - SCOPUS:80052157400

VL - 75

SP - 2120

EP - 2127

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 9

ER -